Crohn’s Disease

February 15, 2016February 15, 2016

Treatment of IBD Moves Forward with Partnership Between Synlogic and AbbVie to Develop New Class of Medicines

Crohn's Disease, IBD News, News, Ulcerative colitis

Synlogic recently announced the establishment of a global Research and Development collaboration with AbbVie to develop innovative medicines for the treatment of inflammatory bowel disease (IBD), taking advantage of Synlogic’s proprietary ... Read more

February 12, 2016February 12, 2016

First Biosimilar Therapy for Crohn’s Disease and Ulcerative Colitis Is Focus of FDA Meeting

Crohn's Disease, IBD News, News, Ulcerative colitis

The U.S. Food and Drug Administration (FDA) Arthritis Advisory Committee recently met to review a biologics license application (BLA) submitted by Celltrion Inc. for its compound CT-P13, a proposed biosimilar to Remicade ... Read more

February 11, 2016February 12, 2016

RedHill Biopharma’s Potential Crohn’s Treatment, RHB-104, Likely to Receive US Patent

Crohn's Disease, IBD News, News

RedHill Biopharma recently announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent covering RHB-104, a new oral combination drug currently being assessed in clinical ... Read more

February 8, 2016February 8, 2016

Fecal Volatile Metabolites May Constitute Valuable Non-invasive Biomarkers for IBD

Crohn's Disease, News, Ulcerative colitis

New research indicates that the analysis of vapors from patients’ fecal samples is a potential non-invasive tool for an early differential diagnosis of inflammatory bowel diseases (IBD), namely Crohn’s disease ... Read more

February 1, 2016February 1, 2016

Advanced Dermatology Partners With Crohn’s & Colitis Foundation for Take Steps Program

Crohn's Disease, IBD News, News

Advanced Dermatology is collaborating with the Crohn’s & Colitis Foundation of America to raise funds and assist CCFA’s Take Steps walk program to support critical research and patient support for the 1.6 million Americans living ... Read more

January 22, 2016January 22, 2016

First Patients Enrolled in Trial for Crohn’s Disease-associated Fistulas

Crohn's Disease, News

Cytori Therapeutics, a company specializing in the development of cell therapies for the treatment of various medical conditions, recently announced the start of a clinical trial for Cytori Cell Therapy, a potential ... Read more

December 7, 2015February 19, 2016

Janssen Submits Crohn’s Disease Drug STELARA for Approval in the United States and European Union

Crohn's Disease, News

Janssen Biotech, Inc. and Janssen-Cilag International NV, both part of the Janssen Pharmaceutical Companies of Johnson & Johnson, recently announced the submission of the company’s product STELARA® (ustekinumab), developed as ... Read more

September 3, 2015September 3, 2015

New Mechanism Underlying Drug Resistance in Crohn’s Disease Identified

Crohn's Disease, News

In a new study entitled “Chronic inflammation up-regulates P-gp in peripheral mononuclear blood cells via the STAT3/Nf-κb pathway in 2,4,6-trinitrobenzene sulfuric acid-induced colitis mice,” researchers identified a mechanism underlying drug resistance ... Read more

August 25, 2015August 25, 2015

TiGenix Lead Compound Cx601 Efficient in Treating CD Patients’ Perianal Fistulas

Crohn's Disease, News

TiGenix, a leading biopharmaceutical company developing therapeutics based on adult stem cells, recently announced the results of the Phase III ADMIRE-CD clinical trial, testing the company’s lead compound Cx601 on Crohn’s disease ... Read more

August 24, 2015August 24, 2015

New Clinical Trial To Assess Long-Term Therapy Efficacy for Perianal Fistulas in CD Patients

Crohn's Disease, News

In a new study entitled “Multimodal treatment of perianal fistulas in Crohn’s disease: seton versus anti-TNF versus advancement platy (PISA): study protocol for a randomized controlled trial,” authors present the ... Read more